Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
OBJECTIVES: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not require INR monitoring. This study evaluated the cost-effectiveness of dabigatran versus vitamin K antagonist...
Main Authors: | Mark Pletscher, Rafael Plessow, Klaus Eichler, Simon Wieser |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2012-12-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/1805 |
Similar Items
-
HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01) -
Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01) -
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
by: Josef Finsterer, et al.
Published: (2012-02-01) -
PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01) -
Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)